HIGH DOSE ACYCLOVIR VERSUS VIDARABINE IN NEONATAL HERPES SIMPLEX INFECTION

高剂量阿昔洛韦与阿糖腺苷治疗新生儿单纯疱疹感染

• 批准号: 6112847
• 负责人: RICHARD J. WHITLEY
• 金额: $ 2.95万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6112847
• 关键词: Herpesviridae disease; acyclovir; central nervous system disorders; clinical research; clinical trial phase I; congenital infection; dosage; herpes simplex virus 1; human morbidity; human mortality; human subject; human therapy evaluation; microorganism disease chemotherapy; newborn human (0-6 weeks)

This collaborative study of neonatal herpes simplex virus infection will evaluate high dose acyclovir (60mg/kg/day) for 21 days in the treatment of neonatal HSV infection in babies with encephalities (CNS) or disseminated.

这项新生儿单纯疱疹病毒感染的合作研究将评估高剂量阿昔洛韦（60 mg/kg/天）治疗21天的新生儿单纯疱疹病毒感染的婴儿与脑病（CNS）或传播。